HST-NEETs + Bone Marrow Transplant for Lymphoma
(BMTCTN1903 Trial)
Recruiting at 15 trial locations
DA
NR
CB
Overseen ByChristine Borchert
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Catherine Bollard
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Research Team
SD
Steve Devine, MD, MS
Principal Investigator
National Marrow Donor Program
Eligibility Criteria
This trial is for individuals at least 15 years old with HIV-associated lymphoma, specifically those who have had two or three prior treatments and are responsive to chemotherapy. They must be planning an autologous stem cell transplant (ASCT) and have a Karnofsky performance status of 70% or higher. People with uncontrolled infections, previous cellular therapies, certain heart conditions, resistant HIV strains, or active CNS involvement cannot participate.Inclusion Criteria
My HIV is under control with medication.
I do not have any infections that aren't under control.
I am at least 15 years old.
See 14 more
Exclusion Criteria
My cancer has spread to my brain or spinal cord.
I am taking more than 0.5 mg/kg/day of steroids.
My HIV is not subtype B.
See 9 more
Treatment Details
Interventions
- Bone Marrow Transplant (Bone Marrow Transplant)
- Busulfan (Alkylating agents)
- HST-NEETs (CAR T-cell Therapy)
Trial OverviewThe trial is testing the effectiveness of HST-NEETs following an autologous stem cell transplant in treating HIV-related lymphomas. It's a Phase II study where all participants receive high-dose chemotherapy followed by ASCT and then the investigational therapy HST-NEETs.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: HST-NEETsExperimental Treatment2 Interventions
HIV+ Participants that were treated with autologous hematopoietic stem cell transplant.
Bone Marrow Transplant is already approved in Canada, Japan for the following indications:
Approved in Canada as Allogeneic Bone Marrow Transplant for:
- Acute Leukemias
- Chronic Leukemias
- Lymphomas
- Multiple Myeloma
- Myelodysplastic Syndromes
- Aplastic Anemia
Approved in Japan as Allogeneic Bone Marrow Transplant for:
- Acute Leukemias
- Chronic Leukemias
- Lymphomas
- Multiple Myeloma
- Myelodysplastic Syndromes
- Aplastic Anemia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Catherine Bollard
Lead Sponsor
Trials
1
Recruited
10+
National Marrow Donor Program
Collaborator
Trials
63
Recruited
202,000+
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Trials
3,987
Recruited
47,860,000+
Blood and Marrow Transplant Clinical Trials Network
Collaborator
Trials
51
Recruited
14,600+
National Cancer Institute (NCI)
Collaborator
Trials
14,080
Recruited
41,180,000+
Children's National Research Institute
Collaborator
Trials
227
Recruited
258,000+